TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30630500

Group type: EXPERIMENTAL
Intervention: Moderate hypofractionated (MHF) group (52 patients in Arms 1-3)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated (EHF) group (30 patients in Arms 4-5)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MHF group (low-risk)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EHF group (low-risk)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MHF group (intermediate risk)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EHF group (intermediate risk)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MHF group (high risk)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EHF group (high risk)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MHF group
Number of subjects: 82

Group type: COMPARATOR
Intervention: EHF group
Number of subjects: 82
Study: 28953501

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study: 28833962

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folic Acid (FA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine plus Lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26394340

Group type: EXPERIMENTAL
Intervention: Digital workflow process
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional pathway
Number of subjects: 20
Study: 23361654

Group type: EXPERIMENTAL
Intervention: Silicone ring tourniquet (SRT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pneumatic cuff tourniquet (PT)
Number of subjects: 50
Study: 21704307

Group type: EXPERIMENTAL
Intervention: Cocaine dependence (CD) participants during reward anticipation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cocaine dependence (CD) participants during reward notification
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control (HC) participants
Number of subjects: 20
Study: 19108741

Group type: EXPERIMENTAL
Intervention: Physician-based education and activation
Number of subjects: 444

Group type: COMPARATOR
Intervention: Rehabilitation program 1
Number of subjects: 444

Group type: COMPARATOR
Intervention: Rehabilitation program 2
Number of subjects: 444
Study: 16141382

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training (80% peak aerobic capacity, T(H))
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training (65% peak aerobic capacity, T(M))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-intensity (stretching) placebo control (50% peak aerobic capacity, C(TB))
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training (T(H))
Number of subjects: 25
Study: 14617222

Group type: EXPERIMENTAL
Intervention: Lispro insulin + NPH insulin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lispro insulin + metformin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular insulin + NPH insulin
Number of subjects: 60
Study: 10685722

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg (Per/Ind)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Atenolol 50 mg (Ate)
Number of subjects: 446
Study: 9086133

Group type: EXPERIMENTAL
Intervention: 500 mg/day hydroxyurea
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1000 mg/day hydroxyurea
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (didanosine therapy only)
Number of subjects: 26
Study: 7886561

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood products usage
Number of subjects: 0
Study: 3761959

Group type: EXPERIMENTAL
Intervention: Carteolol hydrochloride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Timolol maleate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carteolol hydrochloride and Timolol maleate
Number of subjects: 14
Study: 30664008

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon‐α (IFN‐α) 9×10 IU/m, n=125
Number of subjects: 250

Group type: COMPARATOR
Intervention: Continuous intravenous interleukin-2 (IL‐2) 9×10 IU/m, n=125
Number of subjects: 250

Group type: COMPARATOR
Intervention: Continuous intravenous interleukin-2 (IL‐2), n=125
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon‐α (IFN‐α), n=125
Number of subjects: 250
Study: 30040818

Group type: EXPERIMENTAL
Intervention: Tailored multifaceted intervention (n = 154) including physiotherapist-led vestibular rehabilitation (35%), internet-based cognitive-behavioral therapy (19%), Otago home-based exercise program (24%), and medical management (40%)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Usual care (control; n = 151)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Tailored multifaceted intervention
Number of subjects: 305
Study: 27966509

Group type: EXPERIMENTAL
Intervention: Oil pulling with rice bran oil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oil pulling with sesame oil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinsing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of all three interventions
Number of subjects: 30
Study: 25422085

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention aimed at team level, including development of a team specific lifestyle plan and training on creating a healthy environment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 0
Study: 23788468

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) with intravenous (IV) fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: PainBuster (0.5% ropivacaine via a multi‐orifice catheter)
Number of subjects: 40
Study: 19995933

Group type: EXPERIMENTAL
Intervention: 200 mg tafenoquine
Number of subjects: 654

Group type: COMPARATOR
Intervention: 250 mg mefloquine
Number of subjects: 654
Study: 17976222

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg po/d, given for 6‐8 days before surgery)
Number of subjects: 35
Study: 16629348

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 to 300 mg daily)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 40 mg daily)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Bupropion SR and Paroxetine
Number of subjects: 141
Study: 14667956

Group type: EXPERIMENTAL
Intervention: Oral dose of rosuvastatin 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous infusion of rosuvastatin 8 mg over 4 hours
Number of subjects: 10
Study: 11027740

Group type: EXPERIMENTAL
Intervention: Budesonide (mean daily dose of 412 microg, mean cumulative dose of 1.35 g over 9.2 years)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (asthma patients who never received inhaled corticosteroids)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Healthy siblings (serving as controls)
Number of subjects: 211
Study: 9203786

Group type: EXPERIMENTAL
Intervention: Erythromycin (50 mg/kg per day in four divided doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole (10 mg/kg per day of trimethoprim and 50 mg/kg per day of sulphamethoxazole in two divided doses for five days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 48
Study: 1306084

Group type: EXPERIMENTAL
Intervention: Supro isolated soy protein (1.5 g/kg/day, 8 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no soy protein supply)
Number of subjects: 66
Study: 3511977

Group type: EXPERIMENTAL
Intervention: Single administration of E. coli AZ (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiple administrations of E. coli AZ (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (C) receiving no administration
Number of subjects: 60
Study: 31884246

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Aspirin alone (placebo)
Number of subjects: 500
Study: 29885082

Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV) 500 mg 3 times daily for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV)
Number of subjects: 16
Study: 27622961

Group type: EXPERIMENTAL
Intervention: Comprehensive yoga package (including physical asanas, pranayama, and meditation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine physical training activities
Number of subjects: 200
Study: 24863850

Group type: EXPERIMENTAL
Intervention: Bicompartmental knee arthroplasty (BKA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 50
Study: 21451421

Group type: EXPERIMENTAL
Intervention: Eplerenone (100-300 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spironolactone (75-225 mg once daily)
Number of subjects: 0
Study: 17315420

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 22
Study: 12378634

Group type: COMPARATOR
Intervention: OAM: metronidazole 500 mg bid, amoxicillin 1 g bid, omeprazole 20 mg bid
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OAA: azithromycin 1 g od for the first 3 days, amoxicillin 1 g bid, omeprazole 20 mg bid
Number of subjects: 100

Group type: COMPARATOR
Intervention: OAM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OAA
Number of subjects: 100
Study: 9569650

Group type: EXPERIMENTAL
Intervention: Accuracy motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction instructions
Number of subjects: 0
Study: 7985743

Group type: EXPERIMENTAL
Intervention: Exposure to sporozoite‐infected mosquitoes over the previous 28‐day period
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Exposure to more than 10 infective bites during the prior 28‐day period
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Enrollment during the highest incidence period
Number of subjects: 1007
Study: 2694164

Group type: EXPERIMENTAL
Intervention: Chemoprevention intervention (specific details not provided)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Not applicable (control group not mentioned)
Number of subjects: 80
Study: 1119765

Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no hyaluronidase)
Number of subjects: 13
Study: 12492615

Group type: EXPERIMENTAL
Intervention: In-patient pharmaceutical counselling with MIDS and medicine reminder card
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 30944269

Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/d
Number of subjects: 670

Group type: COMPARATOR
Intervention: Metformin 1,500 mg/d
Number of subjects: 670
Study: 29573529

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26719221

Group type: EXPERIMENTAL
Intervention: French language semi-quantitative food frequency questionnaire (FFQ)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: French language semi-quantitative food frequency questionnaire (FFQ) pre-dietary record (DR)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: French language semi-quantitative food frequency questionnaire (FFQ) post-dietary record (DR)
Number of subjects: 53
Study: 25152476

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery plus surgical ventricular reconstruction
Number of subjects: 267

Group type: COMPARATOR
Intervention: Coronary artery bypass surgery alone
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Assessment of myocardial viability
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Presence of anterior wall or apical scar
Number of subjects: 267
Study: 22638922

Group type: EXPERIMENTAL
Intervention: SICS with a conjunctival flap
Number of subjects: 220

Group type: COMPARATOR
Intervention: SICS without a conjunctival flap
Number of subjects: 220
Study: 19855309

Group type: EXPERIMENTAL
Intervention: Circuit Training (CT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pre-Exhaustion (PE)
Number of subjects: 8
Study: 18823203

Group type: EXPERIMENTAL
Intervention: Evolved agent
Number of subjects: 2

Group type: COMPARATOR
Intervention: Human participants
Number of subjects: 2
Study: 16332231

Group type: EXPERIMENTAL
Intervention: beta‐TCP + 0.3 mg/ml rhPDGF‐BB in buffer
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: beta‐TCP + 1.0 mg/ml rhPDGF‐BB in buffer
Number of subjects: 180

Group type: COMPARATOR
Intervention: beta‐TCP + buffer (active control)
Number of subjects: 180
Study: 12215691

Group type: EXPERIMENTAL
Intervention: 100 mg intravenous ketoprofen 30 minutes before surgical incision (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Immediate post-surgical intravenous ketoprofen (Group II)
Number of subjects: 50
Study: 9776040

Group type: EXPERIMENTAL
Intervention: Products designed to regenerate periodontal tissues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regenerative procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human randomized controlled clinical trials
Number of subjects: 0
Study: 7665806

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM) measures
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Positive affect measures
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Negative affect measures
Number of subjects: 21
Study: 2576216

Group type: EXPERIMENTAL
Intervention: 0.10 mg/kg vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.20 mg/kg vecuronium
Number of subjects: 0
Study: 30095728

Group type: EXPERIMENTAL
Intervention: Bedtime administration of aspirin (100 mg)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Daytime administration of aspirin (100 mg)
Number of subjects: 225
Study: 25800211

Group type: EXPERIMENTAL
Intervention: Bromocriptine (1.25mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulpiride (400mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25678774

Group type: EXPERIMENTAL
Intervention: Oxycodone once-a-day controlled-release (CR) tablets (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial products (10 mg bis in die [bid])
Number of subjects: 0
Study: 24188685

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily plus modified FOLFOX-6
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily plus FOLFIRI
Number of subjects: 171

Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg every 2 weeks plus modified FOLFOX-6
Number of subjects: 171

Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg every 2 weeks plus FOLFIRI
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Axitinib plus modified FOLFOX-6
Number of subjects: 171

Group type: COMPARATOR
Intervention: Bevacizumab plus modified FOLFOX-6
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Axitinib plus FOLFIRI
Number of subjects: 171

Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 171
Study: 21615341

Group type: EXPERIMENTAL
Intervention: Spinal bupivacaine 10 mg (Group 1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ropivacaine 10 mg (Group 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ropivacaine 10 mg with sufentanil 2.5 mcg (Group 3)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ropivacaine 10 mg with sufentanil 5 mcg (Group 4)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sufentanil (Groups 3 and 4)
Number of subjects: 64
Study: 19389007

Group type: EXPERIMENTAL
Intervention: RRP with general anaesthesia (R1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PRP with general anaesthesia (P1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RRP with general plus epidural anaesthesia (R2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PRP (P1) and RRP (P2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study: 17007707

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 200

Group type: COMPARATOR
Intervention: Anti-smoking advice
Number of subjects: 200
Study: 15289387

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 249

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 249
Study: 11426071

Group type: EXPERIMENTAL
Intervention: Zidovudine/nevirapine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Triple therapy (zidovudine/didanosine/nevirapine)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Zidovudine/didanosine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 59
Study: 8989008

Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 micrograms/kg i.v. (Group II)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 micrograms/kg epidurally (Group III)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 micrograms/kg epidurally (Group IV)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (Group I: i.v. and epidural saline)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure responses
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Heart rate responses
Number of subjects: 126
Study: 7969216

Group type: EXPERIMENTAL
Intervention: Liquid levodopa/carbidopa (LD/CD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Tablet levodopa/carbidopa (LD/CD)
Number of subjects: 5
Study: 3620048

Group type: EXPERIMENTAL
Intervention: Full-dose (0.5 ml) intramuscular injection of PVRV on days 0, 3, 7, 14 and 28
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 2-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 4-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 1-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Number of subjects: 58
Study: 29203380

Group type: EXPERIMENTAL
Intervention: Periarticular injection (PI)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 129
Study: 27411763

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy-based program for reducing internalized stigma, provided for 8 weeks (12 sessions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 64
Study: 24231135

Group type: EXPERIMENTAL
Intervention: Low-intensity ergometer aerobic training (3 times per week for 6 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no aerobic training)
Number of subjects: 54
Study: 22228560

Group type: EXPERIMENTAL
Intervention: SterolQ₁₀ (100 mg single dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: generic CoQ₁₀ (100 mg single dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SterolQ₁₀ (100 mg/day for 4 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: generic CoQ₁₀ (100 mg/day for 4 weeks)
Number of subjects: 36
Study: 20238367

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Crestal approach to lift the sinus lining with 8 mm implants
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 5 mm short implants
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sinus lift procedures without bone graft
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Bone substitutes
Number of subjects: 250
Study: 19040172

Group type: EXPERIMENTAL
Intervention: LifeMasters Supported SelfCare demonstration program (disease management services)
Number of subjects: 33000
Study: 16162050

Group type: EXPERIMENTAL
Intervention: Placebo expectation with goal activation techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo expectation with negative motivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo effect measures
Number of subjects: 0
Study: 14700097

Group type: EXPERIMENTAL
Intervention: Anterior Chamber Maintainer (ACM) system
Number of subjects: 132

Group type: COMPARATOR
Intervention: No anterior chamber maintainer
Number of subjects: 132
Study: 10320178

Group type: EXPERIMENTAL
Intervention: Topical lidocaine-prilocaine cream (EMLA) applied transdermally for 3 hours before CT removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV morphine administered 0.5 hours before CT removal
Number of subjects: 0
Study: 8943644

Group type: EXPERIMENTAL
Intervention: Stapled closure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sutured closure
Number of subjects: 40
Study: 1767644

Group type: EXPERIMENTAL
Intervention: Full weight bearing allowed after 2-4 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group allowed weight bearing at 4 weeks
Number of subjects: 61
Study: 6127885

Group type: EXPERIMENTAL
Intervention: Prenalterol infusion (5 micrograms/kg/min for 30 min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (5 micrograms/kg/min for 30 min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (5 micrograms/kg/min for 30 min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prenalterol infusion
Number of subjects: 32
Study: 30266892

Group type: EXPERIMENTAL
Intervention: CCNU + BEV
Number of subjects: 296

Group type: COMPARATOR
Intervention: CCNU + placebo
Number of subjects: 296
Study: 30701113

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide irrigation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no hydrogen peroxide irrigation)
Number of subjects: 117
Study: 27993193

Group type: EXPERIMENTAL
Intervention: Bilberries (150 g, 3 times a week for 6 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bilberries (150 g, 3 times a week for 6 weeks) in men
Number of subjects: 36
Study: 24797228

Group type: EXPERIMENTAL
Intervention: Triclosan-coated polyglactin 910 antimicrobial sutures
Number of subjects: 198

Group type: COMPARATOR
Intervention: Conventional wound closure
Number of subjects: 198